Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 4Sarcoma 1

Conditions

Sarcoma 25Central Nervous System Neoplasms 18Astrocytoma 15Gliosarcoma 14Glioblastoma 14Ovarian Neoplasms 12Oligodendroglioma 10Neuroectodermal Tumors, Primitive, Peripheral 10Brain Neoplasms 10Osteosarcoma 9Neuroblastoma 9Testicular Neoplasms 8Glioma 8Dendritic Cell Sarcoma, Interdigitating 8Medulloblastoma 7Breast Neoplasms 7Choroid Plexus Neoplasms 6Carcinosarcoma 6Burkitt Lymphoma 6Wilms Tumor 5Testicular Germ Cell Tumor 5Stomach Neoplasms 5Rhabdoid Tumor 5Optic Nerve Glioma 5Neoplasms 5Lymphoma, Non-Hodgkin 5Lymphoma, Large B-Cell, Diffuse 5Kidney Neoplasms 5Head and Neck Neoplasms 5Retinoblastoma 4

Interventions

temsirolimus 1linrodostat 1ixabepilone 1Taxes 1Sunitinib 1Sirolimus 1Paclitaxel 1Nivolumab 1Laparoscopy 1Immunoglobulin G 1Epothilones 1Disulfides 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Adenocarcinoma × Carboplatin × Sarcoma × Clear all
NCT00977574 2026-05-29

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
349 enrolled 11 charts
GynecologicSarcoma

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡